Quick Search

  Wholesaler/Distributor Registration   l  My Cart   l   My Account  l  Home

  Pharmacist Nutriceuticals®
  USA Best®
  Health Concerns
  Sexual Health
  Specialty Supplements
  Vitamins & Minerals
  Weight Loss
  Sports & Athletic Nutrition
  Extreme Hardcore Body Building
  Body Shaping
  Amino Acids
  Food Bars
  Branded Ingredients
  Press Releases
  Company Policy
LADY'S PAK™ [click to enlarge]
USALPA - 18#

MSRP: $54.99
Internet Direct: $49.99


Lady's Vitamin & Mineral Pak 30 packets with 8 menstrual cycle packets for the active women.

"Nutrition, The Best Women Athletes Get It!"

Pharmacist References:

Vitamin A References:
1. Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995;333:1369-73.
2. Mastroiacovo P, Mazzone T, Addis A, et al. High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. Teratology 1999;59:7-11.
3. Bendich A, Langseth L. Safety of vitamin A. Am J Clin Nutr 1989;49:358-71.
4. Mejiaa LA, Chew F. Hematological effect of supplementing anemic children with vitamin A alone and a combination with iron. Am J Clin Nutr 1988;48:595-600.

Vitamin D References:
1. Hayes CE, Cantorna MT, Deiuca HF. Vitamin D and multiple sclerosis. Proc Soc Exper Biol Med 1997;216:21-27.
2. Labriji-Mestaghanmi H, Billaudel B, Garnier PE, Sutter BCJ. Vitamin D and pancreatic islet function 2. Time course for changes in insulin secretion and content during vitamin deprivation and repletion. Endocrine Invest 1988;11:577-87.
3. time course for changes in insulin seretion and content during vitamin deprivation and repletion Endocrine invest 1988,11.577-87.
4. Boucher BJ. Indequate vitamin D status: does it contribute to the disorders comprising syndrom 'X'? Br J Nutr 1998;79:315-27.
5. Chapuy M-C, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficency in an adult normal population. Osteoporosis Int 1997;7:439-43.
6. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl Meg 1998;338:777-83.
7. Dawson-Hughes B, Harris SS, Krall EA, et al. Rates of bone loss in postmenopausal women randomly assigned to one of twn dosages of vitmain D. Am J Clin Epidemio 1997,50:967-73.
8. Lind L, Sakrfors F, Rerglund L, et al. Serum calcium: A new independent prospective risk factor formula of myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemio 1997,50:967-73.
9. Heikkinen A0M, Tuppurainen MT, Komulainen M, et al. Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur J Endocrinol 1997;137:495-502.
10. Scragg R, Khaw K-T, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 1995;49:640-46.

Vitamin E References:
1. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-56.
2. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1444-49.
3. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-86.
4. Christen S, Woodall AA, Shigenage MK, Southwell-Keely, Duncan MW, Ames BN. Gamma-tocopherol traps mutagenic electrophiles such as NO+ and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci 1997;94:3217-22.
5. Rimm E. Micronutrients, Coronary Heart disease and cancer: Should we all be on supplements? Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.

Pantothenic Acid References:
1. Fidanza A. Therapeutic action of pantothenic acid. Int J Vit Nutr Res 1983;suppl 24-53-67 [review].

Vitamin B6 References:
1. Keniston RC, Nathan PA, Leklem JE, Lockwood Rs. Vitamin B6, vitamin C, and carpal tunnel syndrome. J Occup Environ Med 1997;39:949-59.
2. Franzblau A, Rock CL, Werner RA, et al. The relationship of vitamin B6 status to median nerve function and carpal tunnel syndrome among active industrial workers. J Occup Environ Med 1996;38:485-91.
3. Smith GP, Rudge PJ, Peters TJ. Biochemical studies of pyridoxal and pyridoxal phosphate status and therapeutic trial of pyridoxine in patients with carpal tunnel syndrome. Ann Neurol 1984;15:104-107.
4. Gaby AR. Literature review & commentary. Townsend Letter for Doctors June 1990;338-39.
5. Parry G, Bredesen DE. Sensory neuropath with low-dose pyridoxine. Neurology 1985;35:1466-68.
6. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N England Med 1983;309(8):445-48.

Vitamin B12 References:
1. Ellis FR, Nasser S. A pilot study of vitamin B12 in the treatment of tiredness. Br J Nutr 1973;30:277-83.
2. Lapp CW, Cheney PR. The rationale for using high-dose cobalamin )vitamin B12). CFIDS Chronic Physicians' Forum, 1993;Fall:19-20.
3. Rana S, D'Amico F, Merenstein JH. Relationship of vitamin B12 deficiency with incontinence in old people. J Am Geriatr Soc 1998;46:931 [letter].
4. Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B12, and folate in elderly women. Am J Clin Nutr 1999;69:564-71.
5. Goldberg TH. Oral vitamin B12 supplementation for elderly patients with B12 deficiency. J Am Geri Soc 1995;43:SA73 [abstr#P258].
6. Lederle FA. Oral cobalamin for pernicious anemia-medicine's best kept secret? JAMA 1993;264:94-95 [commentary].
7. Kondo H. Haematological effects of oral cobalamin preparations on patients with megaloblasic anemia. Acta Haematol 1998;99:200-205.
8. Waif SO, Jansen CJ., Crabtree RE, et al. Oral vitamin B12 without intrinsic factor in the treatment pernicous anemia. Ann Intern Med 1963;58:810-17.
9. Crosby WH. Oral cyanocobalamin without intrinsic factor for pernicious anemia. Arch Intern Med 1980;140:1582.
10. Kaufman W. The use of vitamin therapy to reverse certain concomitants of aging. J Am Geriatr S 1955;3:927-36.
11. Lindenbaum J, Rosenberg IH, Wilson PWF, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994;60:2-11.
12. verhaeverbeke I, mets T, Mulkens K, vandewoulde M. Normalization of low vitamin B12 serum levels in older people by oral treatment. J Am Geriatr Soc 1997;45:124-25 [letter].

Folic Acid References:
1.Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. JAMA 1995;274:1698-17.
2. Shaw GM, O'Malley CD, Wasserman CR, et al. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deciciencies among offspring. Am J Med Gentetics 1995;59:536-45.
3. Tolarova M. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip. Lancet 1982;ii:217 [letter].
4. Shaw GM, Lammer EF, Wasserman CR, et al. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 14995;345:393-96.
5. Hayes C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptional folic acid supplementation and oral clefts. Am J Epidemiol 1996;143:1229-34.
6. Russel RM. A minimum of 13,500 deaths annually from coronary artery disease could be prevented by increasing folate intake to reduce homocysteine levels. JAMA 1996;274:1828-29.
7. Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B-12, and folate in elderly women. Am J Clin Nutr 1999;69:564-71.
8. Butterworth CE Jr, Tamua T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989;50:353-58.
9. Wald NJ, Bower C. Folic acid, pernicious anaemia, and prevention of neural tube defects. Lancet 1994;343:307.
10. Russell RM, Golner BB, Krasinski SD, et al. Effect of antacid and H2 receptor antagonists on the intestinal absorption of folic acid. J Lab Clin Med 1988;112:458-63.
11. Russell RM, Dutta SK, Oaks EV, et al. Impariment of folic acid absorption by oral pancreatic extracts. Dig Dis Sci 1980;25:369-73.

Biotin References:
1. Said HM, Redha R, Nylander W. Biotin transport in the human intestine: Inhibition by anticonvulsar drugs. Am J Clin Nutr 1989;49:127-31.
2. Zempleni J, Mock DM. Biotin biochemistry and human requirements. J Nutr Biochem 1999;10:128-38 [review].
3. Coggeshall JC et al. Biotin status and plasma glucose in diabetics. Ann NY Acad Sci 1985;447:38
4. Koutsikos D. Agroyannis B, Tzanatos-Exarchou H, Biotin for diabetic peripheral neuropathy. Bio Pharmachother 1990;44:511-14.
5. Hochman LG, Scher RK, Meyerson MS. Brittle nails. Responses to daily biotin supplementation. Curtis 1993;51(4):303-5.
6. Gomer E. The Essential Guide to Vitamins and Mineral New York Harger, 1995;70-72.

Molybdenum References:
1. Johnson JL et al. Molybdenum cofactor deciciency in a patient previously characterized as deficient sulfite oxidase. Biochem Med Metabol Biol 1988;40:86-93.

L-carnitine References:
1. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic effica of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-
2.Giamberardino MA et al. Effects of prolonged L-carnitine adminstration on delayed muscle pain an CK release after eccentric effort. Int J Sports Med 1996;17:320-24.
3. Green RE, Levine AM, Gunning MJ. The effect of L-cartine supplementation on lean body mass male amateur body builders. J AM, Dietet Assoc 1997;(syook):A-72.
4. Murray MT. The many benefits of carnitine. Am J Natural Med 1996;3:6-14 [review].
5. Dal Negro R, Pomari G, et al. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabo and ventilatory response in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1986;24:453-56.
6. Dal Negro R, Turco P, Pomari C, De Conti F. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1988;26:269-72.
7. Dipalma JR. Carnitine deficiency. Am Family Phys 1988;38:243-51.
8. Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373-90.


9. Del Favero A. Carnitine and gangliosides. Lancet 1988;ii:337 [letter].
10. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure-experimental and clinical study. Jpn Circ J 1992;56:86-94.

Vitamin C References:
1. Balz F. Antioxiant vitamins and heart disease. Presented at the 60th Annual Biology Colloquium, Oregon State University, Corvallis, Oregon, February 25, 1999.
2. Hemilä H. Does vitamin C alleviate the symptoms of the common cold? A review of current evidence Scand J Infect Dis 1994;26:1-6
3. Taddei S, Virdis A, Ghaidoni L, et al. Vitamin C improves endotheoium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation
4. Chambers JC, McGregor A, Jean-Marie J, et al. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156-60.
5. Taylor A. Cataract: relationship between nutrition and sxidation. J Am Coll Nutr 1993;12:138-46 [review].
6. Taylor A, Jacques PF, Nadler D, et al. Relationship in humans between ascorbic acid consumption and levels of total and reduced ascorbic acid in lens, aqueous humor, and plasma. Curr Eye Res 1991;10:751-59.
7. Jacques PF, Chylack LT Jr. Epidemiologic evidence of a role for the antioxidant vitamins and carotenoids in cataract prevention. Am J Clin Nutr 1991;53:352S-55S
8. Jacques PF, Chylack LT, McGandy RB, Hartz SC. Antioxidant status in persons with and without senile cataract. Arch Ophthalmol 1988;106:337-40.
9. Robertson JM, Donner AP, Trevithick JR. vitamin E intake and risk of cataracts in humans Ann Nrl Acad Sci 1989;570:372-82.
10. Seddon JM, Christen WG, Manson JE, et al. The use of vitamin supplements and the risk of cataract among US male physicians. Am J Public Health 1994;84:788-792.
11. Vincent TE, mendiratta S, may JM. Inhibition of aldose reductase in human erythrocytes by vitamin C. diabetes Res Clin Pract1 999;43:1-8.
12. Simon JA. Ascorbic acid and cholesterol gallstones. Med Hypotheses 1993;40:81-84.
13. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996;93:3704-709
14. Sandstead HH. Copper bioavailability and requirements. Am J clin Nutr 1982;35:809-14 [review].
15. Finley EB, Cerklewski FL. Influence of ascorbic acid supplementation on copper status in yound adult men. Am J Clin Nutr 1983;37:553-56.
16. Piesse JW. Nutritional factors in calcium containing kidney stones wiht particular emphasis on vitamin C. Int Clin Nutr Rev 1985;5(3):110-129 [review]
17. Ringsdorf WM, Cheraskin WM. Medical complications from ascorbic acid: review and interpretation (part one). J Holistic Med 1984;6(1):49-63.
18. Hoffer A. Ascorbic acid and kidney stones. Can Med Assoc J 1985;32:320 [letter]
19. Wandzilak TR, D'Andre SD, Davis PA, Williams HE. Effect of high dose vitamin C on urinary oxal levels. J Urol 1994;151:834-37.
20. Levine M. Vitamin C and optimal health. Presented at the February 25, 1999 60th Annual Biology Colloquium, Oregon State University, Corvallis, Oregon.
21. Levine M, Conry-Cantilena C, wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers:evidnece for a recommended dietary allowance. proc Natl Acad Sci USA 1996;93:3704-709.
22. Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Eur J Clin Invest 1998;28:695-700.

Copper References:
1. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper Am J Clin Nutr 1995;61(suppl):62S-64S.
2. Broun ER. Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of siderobla anemia and bone marrow depression. JAMA 1990;264:1441-43.
3. Jacob RA, Skala JH, Omaye ST, Turnlund JR. Effect of varying ascorbic acid intakes on copper absorption and ceruloplasmin levels of young men. J Nutr 1987;117:2109-15.

Bromelain References:
1. Izaka K, Yamada M, Kawano T, Suyama. T. Gastrointestinal absorption and anti-infammatory effects of bromelain. Jpn J Pharmacol 1972;22:519-34.
2. Balakrishnan V, Hareendran A, Sukumaran Nair C. Double-blind cross-over trial of an enzyme preparation in pancreatic steatorrhea. J Assoc Phys Ind 1981;29:207-9.
3. Seligman B. Bromelain: An anti-inflammatory agent. Angiology 1962;13:508-10.
4. Cirelli MG. Treatment of inflammation and edema with bromelain. Delaware Med J 1962;34(6):159-67.
5. Masson M. Bromelain in the treatment of blunt injuires to the musculoskeletal system. A case observation study by an orthopedic surgeon in private practive. Fortschr Med 1995;113(19):303-6.
6. Seltzer AP, Minimizing post-operative dedema and ecchymoses by the use of an oral enzyme preparation (bromelain). EENT Monthly 1962;41:813-17.
7. Howat RCL, Lewis GD. The effect of bromelain therapy of episiotomy woulnds-a double blind controlled clinical trial. J Obstet Gynaecol Br Commonwealth 1972;79:951-53.
8. Zatuchni GI, Colombi DJ. Bromelains therapy for the prevention of episiotomy pain. Obstet Gynec 1967;29:275-78.
9. Taub SJ. The use of Ananase in sinusitis. A study of 60 patients. EENT Monthly 1966;45:96-98.
10. Ryan RE. A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis. Headache 1967;7:13-17.
11. Mori S, Oijima Y, Hirose T, et al. The clinical effect of proteolytic enzyme containing bromelain and typsin on urinary tract infection evaluated by double blind method. Acta Obstet Gynaecol Jpn 1972;19:147-53.
12. Cohen A, Goldman J. Bromelains therapy in theumatoid arthritis. Pennsylvania Med J 1964;67:27-30.
13. Heinicke R, van der Wal L, Yokoyama M. Effect of bromelain (Ananase) on human platelet aggregation. Experientia 1972;28:844-45.
14. Nieper HA. Effect of bromelains on coronary heart disease and angina pectoris. Acta Med Empiric 1978;5:274-78.
15. Seligman B. Oral bromelains as adjunts in the treatment of acute thrombophletbitis. Angiology 1969;20:22-26.
16. Schafer A, Adelman B. Plasma inhibition of platelet function and of arachidonic acid metabolism. Clin Invest 1985;75:456-61.
17. Kelly GS. Bromelain a literature review and discussion of its therapeutic applications. Alt Med Rev 1996;1:243-57 [review].
18. Gaby AR. The story of bromelain. Nutr Healing May 1995;3,4,11.
19. Gutfreund AE, Taussig SJ, Morris AK. Effect of oral bromelain on blood pressure and heart rate hypertensive patients. Hawaii Med J 1978;37:143-46.

Ginkgo Biloba References:
1. Drieu K. Preparation and definition of Ginkgo biloba extract. In: Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic, ed. EW Funfgeld. Berlin: Springer-Verlag, 32-36.
2. Krieglstein J. Neuroprotective properties of Ginkgo biloba--constituents. Zeitschrift Phytother 1994;15:92-96.
3. Bruno C, Cuppini R, et al. Regeneration of motor nerves in bilobalide-treated rats. Planta Medica 1993;59:302-7.
4. Clostre F. From the body to the cellular membranes: the different levels of pharmacological actions Ginkgo biloba extract. In Rokan ( Ginkgo biloba): Recent Results in Pharmacology and Clinic, ed Funfgeld. Berlin: Springer-Verlag, 1988, 180-98.
5. Jung F, Mrowietz C, et al. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation volunteers. Arzneim-Forsch Drug Res 1990;40:589-93.
6. Itil Eralp E, Tsambis E, et a. Central nervous system effects of Ginkgo biloba, a plant extract. A J Therapeutics 1996;3:63-73.
7. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American Egb Study Group. JAMA 1997;278:1327-32.
8. Hofferbeth B. The efficacy of Egb 761 in patients with senile dementia of the Alzheimer type, a double-blind, place-bo-controlled study on different levels of investigation. Human Psychopharmacol 1994;9:215-22.
9. Kanowski S, Hermann W, Stephan K, et al. Proof of efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimers type or multi-infarct demential. Pharmacopsychiarty 1996;29:47-56.
10. Ferrandini C, Droy=Lefaix MT, Christen Y, eds. Ginkgo biloba Extract (Egb 761) as a Free Radic Scavenger. Paris: Elsevier, 1993.
11. Lebuisson DA, Leroy L, Rigal G. Treatment of senile macular degeneration with Ginkgo biloba extract. A preliminary double-blind, drug versus placebo study. Presse Med 1986;15:1556-58 [in French].
12. Lanthony P, Cosson JP. Evolution of color vision in diabetic retinopathy treated by extract of Ginkgo biloba. J Fr Ophthalmol
1988;11:671-74 [in French].
13. Harman D. Free radical theory of aging: a hypothesis on pathogenesis of sevile dementia of the Alzheimer's type. Age 1993;16:23-30.
14. Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients: Efficacy of Ginkgo biloba extract (Egb 761) in combination with antidepressants. Geriatr Forsch 1993;3:45-53.
15. Lamant V, Mauco G, et al. Inhibition of the metabolism of platelet-activating factor (PAF-acether) three specific antagonists from Ginkgo biloba. Biochem Pharmacol 1987;36:2749-52.
16. Kroegel C, The potential pathophyisological role an therapeutic implications of platelet activating factor in diseases. Klir Wochenshr 1988;66:373-78.
17. Kroegel C, Kortsik C, et al. The pathophysiological role and therapeutic implications of platelet activating factor in diseases of aging. Drugs Aging 1992;2:345-55.
18. Kriegstein J. Neuroprotective properties of Ginkgo biloba-constituents. Zeitschrift Phytother 1994;15:92-9.
19. Haguenauer JP, Contenot F, Koskas H, Pierart H. Treatment of equilibrium problems with extract Ginkgo biloba. Multicenter, double-blind, placebo-controlled study. Presse Med 1986;15:1569-72 [in French].
20. Meyer B. A multicenter, double-blind, drug versus placebo study of Ginkgo biloba extract in the treatment of tinnitus. Press Med 1986;15:1562-64 [in French].
21. Blumenthal M, Busse WR, Goldberg A, et al eds. The Complete Commission E Monographs: Theraupeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 136-38.

Black Cohosh References:
1. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics, 2d ed. New York: John Wiley & Sons, 1996,88-89.
2. Castleman M. The Healing Herbs. Emmaus, PA: Rodale Press, 1991,75-78.
3. Foster S. Herbs for Your Health. Loveland, CO: Interweave Press, 1996, 12-13.
4. Duker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from Climicifuga racemosa on gonadotropin release in menopausal women and ovairectomized rats. Planta Medica 1991;57:420-2.
5. Kadota S, Li JX, Litt Y, et al. Effects of cimicifugae rhizome on serum calcium and phosphate levels low calcium dietary rats and on bone mineral density inovariectomized rats. Phytomed 1996/7;3:379-85.
6. Murray MT. The Healing Power of Herbs. Rocklin, CA: Prima Publishing, 1995, 376.
7. Bradley PR, ed. Bristish Herbal Compendium, vol 1. Bournemouth, Dorset, UK: Bristish Herbal Medicine Association, 1992, 34-36.
8. Blumenthal M, Busse WR, Goldberg A, et ad, eds. The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 9
9. Gruenwald J. Standardized black cohosh (Cimicifuga) extract clinical monograph. Quart Rev Nat Med 1998; Summer:17-25.

Dong Quai Refernces:
1. Foster S, Yue CX. Herbal Emissaries. Rochester, VT: Healing Arts Press, 1992, 65-72.
2. Hirata JD et al. Does quai have estrogenic effects in postmenopausal women? A double-blind placebo-controlled trial. Fertil Steril 1997;68:981-86.
3. Qi-bing M, Jing-yi T, Bo C. Advance in the pharmacological studies of radix Angelica sinensis (Olive) Diets (Chinese danggui). Chin Med J 1991;104:776-81.
4. Foster S, Herbs for your Health. Loveland, CO: Interweave Press, 1996, 28-29.
5. Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals London: Pharmaceutical Press, 1996, 28-29.

Boron References:
1. Nielsen FH. Boron-an overlooked element of potential nutritional importance. Nutr Today 1988;23:4-7.
2. Nielson FH. facts and fallacies about boron. Nutr Today May/Jun 1992; 6-12.
3. Kelly GS. Boron: a review of its nutrtional interactions and therapeutic uses. Alt Med Rev 1997;2:48-56 [review].
4. Nielson FH. Ultratrace mineral: Boron. In Modern Nutrition in Health and Disease, by Shils ME, V Young, Philadelphia: Lea & Febiger, 188;281-83 [review].
5. Hunt CD, Herbell JL, Nielson FH. Metabolic responses of postmenopausal women to supplemental dietary boron and aluminum during usual and low magnesium intake: boron, calcium, and magnesium absorption and retention and blood mineral concentrations. Am J Clin Nutr 1997;65:803-13.
6. Nielson FH, Hunt CD, Mullen LM, Hunt JR. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. FASEB J 1987;1:394-97.

Vanadium References:
1. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin dependent diabetes melitus. Metab Clin Exp 1996;45(9):1130-35.
2. Naylor GJ. Vandium and manic depressive psychosis. Nutr Health 1984;3:79-85 [review].
3. Chakraborty A, Ghosh R, Roy K, et al. Vandium: A modifier of drug metabolizing enzyme patterns and its critical role in cellular proliferation in transplantable murine lymphoma. Oncology 1995;52:310-14.

Calcium References:
1. Osborne CG, McTyre RB, Dudek J, et al. Evidence for the relationship of calcium to blood pressure Nutr Rev 1996;54:365-81.
2. Barilla DE, Notz C, Kennedy D, Pak CYC. Renal oxalate excretion following oral oxalate loads in patrients with ileal disease and with renal and absorptive hypercalciurias: effect of calcium and magnesium. Am J Med 1978;64:579-85.
3. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med
4. Bell L, Hastenson CE, Halstenson CJ, et al. Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med 1992;152:2441-44.
5. Sheihk MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987;317:532-36.
6. Levenson DI, Bockman RS. A review of calcium preparations. Nutr Rev 1994;52:221-32 [review].
7. Nicar MJ, Pak CYC. Calcium bioavailability from calcium carbonate and calcium citrate. J Clin Endocrinol Metabo 1985;61:391-93.
8. Harvey JA, Kenny P, Poindexter J, pak CYC. Superior calcium absorption from calcium citrate than calcium carbonate using external forearm counting. J Am Coll Nutr
9. Sheikh MS, Santa Ana CA, Nicar MJ, et at. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987;317:532-36.
10. Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary billiary cirrhosis. Am J Clin Nutr 1982;36:426-30.
11. Heaney RP, Recker RR, Weaver CM. Absorbability of calcium sources: the limited role of solubitt Calcif Tissue Int 1990;46:300-4.
12. Deroisy R, Zartarian M, Meurmans L, et al. Acute changes in serum calcium and parathyroid hormaone circulating levels induced by the oral intake of five currently available calcium salts in healthy male volunteers. Clin Rheumatol 1997;16:249-53.
13. Burros M. Testing calcium supplements for lead. New York Times June 4, 1997,B7.
14. Bourgoin BP, Evans DR, Cornett JR, et al. Lead content in 70 brands of dietary calcium supplements. Am J Publ Health 1993;83:1155-60.
15. Civitelli R, Villareal DT, Agnusdei D, et al. Dietary L-lysine and calcium metabolism in humans. Nutrition 1992;8:400-5.
16. Flodin NW. The metabolic roles; pharmacology, and toxicology of lysine. J Am Coll Nutr 1997;16:7-21 [rview].

Iron References:
1. Sullivan JL. Stored iron and ischemic heart disease. Circulation 1992;86:1036 [editorial].
2. Cutter P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 1989;38:1207-10.
3. Stevens RG, Graubard BI, Micozzi MS, et al. Moderate elevation of body iron level and increased of cancer occurrence and death. Int J Cancer 1994;56:364-69.
4. Weinberg ED. Iron withholding a defense against infection and neoplasia. Am J Physiol 1984;64:65-102.
5. Oh VMS. Iron dextra and systemc lupus erthematosus. Br Med J 1992;305:1000 [letter].
6. Dabbagh AJ, Trenam CW, Morris CJ, Blake R. Iron in joint inflammation. Ann Rheum Dis 1993;52:67-73.
7. Salonen JU, Nyyssonen K, Korpela H, et al. High stored iron levels associated with excess risk of myocardial infarction in western Finnish men. Circulation 1992;86:8031-11.
8. Kechi S, Willett J, Egger G, et al. Body iron stores and the risk of carolid atherosclerosis. Circlution 1997;96:3300-3307.
9. Tzonou A, Lagiou P, Trichopoulou A, Tsousos V, Trichopoulos D. Dietary iron and coronary heart disease risk: a study from Greece. Am J Epidemiol 1998;147:161-66.
10. Danesh J, Appleby p. Coronary heart disease and iron status. Meta-analyses of prospective studies Circulation 1999;99:852-54.
11. Hunt JR, Gallagher SK, Johnson LK. Effect of ascorbic acid on apparent iron absorption by women with low stores. Am J Clin Nutr 1994;59:1381-85.
12. Suharno D, West CE, Muhilai, et al. Supplementation with vitamin A and iron for nutritional anemi, in pregnant women in West Java, Indonesia. Lancet 1993;342:1325-28.
13. Semba RD, Muhlai, West KR, Jr, et al. Impact of vitamin A supplementation on hematological indicators of iron metabolism and protein status in children. Nutr Res
14. Harness JAL, Blake DR. Penicllamine nephropathy and iron. Lancet 1982;ii:1368-69.

Magnesium References:
1. Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. Ophthalmologica 1995;209:11-13.
2. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertension patients. Hypernsion 1998;32:260-65.
3. Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD): Positive response to magnesium oral loading test. Magnesium Res 1997;10:149-56.
4. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991;337:757-60.
5. Howard JM, Davies S, Hunnisett A. Magnesium and chronic fatigue syndrome. Lancet 1992;340:426.
6. Gantx NM. Magnesium and chronic fatigue. Lancet 1991;338:66 [letter].
7. Hinds G, Bell NP, McMaster D, McCluskey DR. Normal red cell magnesium concentrations and magnesium loading tests in patients with chronic fatigue syndrome. Ann Clin Biochem 1994;31(Pt 5):459-61.
8. Weisinger JR, Bellorin-font, E. Magnesium and phosphorus. Lancet 1998;352:391-96 [review].

Selenium References:
1. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957-63.
2. Yoshizawa K, Wilett WC, Morris SJ, et al. Study of prediagnostic selenium levels in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24.
3. Yu S-Y, Li W-G, Zhu Y-J, et a. Chemoprevention trial of human hepatitis with selenium supplementation in China. Biol Trace Element Res 1989;20:15-20.
4. Peretz A, Neve J, Desmedt J, et al. Lymphocyte response is enhanced by supplementation of elde subjects with selenium-enriched yeast. Am J Clin Nutri 1991;53:1323-28.
5. Scott R, Mocpherson A, Yates RWS, et al. The effect of oral selenium supplementation on human sperm motitlity. Br J Urol 1998;82:76-80.
6. Dworkin BM. Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS). Chem Biol Iteract 1994;91:181-869.
7. Moore JA, Noiva R, Wells IC. Selenium concentrations in plasma of patients with arteriographically defined coronary atherosclerosis. Clin Chem 1984;30:1171-73.
8. Contempre B, Dumont JE, Ngo B, et al. Effects of selenium supplementation in hypothyroid subject of an iodine and selenium deficient area: The possible danger of indiscriminate supplementation of iodine deficient subjects with selenium. J Clin Endocrinol Metabol 1991;73:213-15.

Zinc References:
1. Mossad SB, Macknin ML, Medendorp SV, et al. Zinc gluconate lozenges for treating the common cold. Ann Int Med
2. Anonymous. Zinc lozenges reduce the duration of common cold symptoms. Nutr Rev 1997;55:82-88 [review].
3. Garland ML, Hagmeyer KO. The role of zinc lozenges in treatment of the common cold. Ann Pharmacother 1998;32:63-69 [review].
4. Macknin ML, Piedmonte M, Calendine C, et al. Zinc gluconate lozenges for treating the common cold in children. A randomized controlled trial. JAMA 1998;279:192-67.
5. Eby G. Where's the bias? Ann Intern Med 1998;128:75 [letter].
6. Petrus EJ, Lawson KA, Bucci LR, Blum K. Randomized, double-masked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptons in allergy-tested subjects. Curr Ther Res 1998;59:595-607.
7. Weismann K, Jakobsen JP, Weismann JE, et al. Zinc gluconate lozenges for common cold. A double-blind clinical trial. Dan Med Bull 1990;37:279-81.
8. Cherry FF, Sandstead HH, Rojas P, et al. Adolescent pregnancy: associations among body weight, zinc nutriture, and pregnancy outcome. Am J Clin Nutr 1989;50:945-54.
9. Goldenberg RL, Tamura T, Neggers Y, et al. The effect of zinc supplementation on pregnancy outcome. JAMA 1995;274:463-68.
10. Prasad A. Discovery of human zinc deficiency and studies in an experimental human model. Amer clin Nutr 1991;53:406-13 [review].
11. Chandra RK. Excessive intake of zinc impairs immune responses. JAMA 1984;252(11):1443.
12. Bush Al, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A8 amyloid formation by zinc. Science 1994;265:1464-65.
13. Potocnik FCV, van Rensburg SJ, Park C, et al. Zinc and platelet membrane microviscosity in Alzheimer's disease. S Afr Med J 1997;87:1116-19.
14. Prasad AS. Zinc in human health: an update. J Trace Elements Exper Med 1998;11:63-87.
15. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion-a reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990;264:1441-43.
16. Resiser S, et al. Effect of copper intake on blood colesterol and its lipoprotein distribution in men. Nutr Rep Internat 1987;36(3):641-49.
17. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am Jclin Nutr 1995;61(suppl):621S-24S [review].
18. Fischer PWF, Girous A, Labbe MR. Effect of zinc supplementation on copper status in adult man. Am J Clin Nutr
19. Dawson EB, Albers J, McGanity WJ. Serum zinc change due to iron supplementation in teenage pregnancy. Am J Clin Nutr 1990;50:848-52.
20. Crofton RW, Gvozdanovic D, Gvozanovic S, et al. Inorganic zinc and the intestinal absorption of ferrous iron. Am J Clin Nutr 1989;50:141-44.
21. Argiratos V, Samman S. The effect of calcium carbonate and calcium citrate on the absorption of zinc in healthy female subjects. Eur J Clin Nutr 1994;48:198-204.
22. Spence H, Norris C, Williams D. Inhibitory effects of zinc on magnesium balance and magnesium absorption in man. J Am Coll Nutr 1994;13:479-84.
23. Brumas V, Hacht B, Filella M, Berthon G. Can N-acetyl-L-cysteine affect zinc metabolisms when used as a paracetamol antidote? Agents Actions 1992;36:278-88.

Manganese References:
1. Raloff J. Reasons for boning up on manganese. Science Sep 1986, 199[review].
2. Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270-74.
3. Freeland-Graves JH. Manganese: an essential nutrient for humans. Nutr Today 1989;23:13-19 [review].

Chromium References:
1. Saner G, Yüzbasiyan V, Neyzi O, et al. Alterations of chromium metabolism and effect of chromium supplementation in Turner's syndrome patients. Am J Clin Nutr 1983;38:574-78.
2. Riales R, Albrink MJ. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. Am J Clin Nutr 1981;34:2670-78.
3. Wang MM, Fox EZ, Stoecker BJ, et al. Serum cholesterol of adults supplemented with brewer's yeast or chromium cholride. Nutr Res 1989;9:989-98.
4. Page TG, Ward TL, and Southern LL. Effect of chromium picolinate on growth and carcass characteristics of growing-finishing pigs. J Animal Sci 1991;69:356.
5. Lefavi R, Anderson R, Keith R, et al. Efficacy of chromium supplementation in athletes: Emphasis on anabolism. Int J Sport Nutr 1992;2:111-22.
6. McCarty MF. The case for supplemental chromium and a survey of clinical studies with chromium picolinate. J Appl Nutr 1991;43:59-66.
7. Hallmark MA, Reynolds TH, DeSouza CA, et al. Effects of chromium and resistive training on muscle strength and body composition. Med Sci Spt Ex 1996;28:139-44.
8. Kaats GR, Blum K, Fisher JA, Adelman JA. Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo-controlled study. Curr Ther Res 1996;57:747-51.
9. Kaats GR, Blum K, Pullin D, Keither SC, Wood R. A randomized, double-masked, placebo-control study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study. Curr Ther Res 1998;59:379-88.
10. Sterns DM, Belbruno JJ, Wetterhahn KE. A prediction of chromium (III) accumulation in humans from chromium dietary supplements. FASEB J 1995;9:1650-57.
11. Sterns DM, Wise JP, Patierno SR, Wetterhahn KE. Chromium (III) picolinate produces chromosl damage in Chinese hamster ovary cells. FASEB J 1995;9:1643-49.
12. Garland M, Morris JS, Colditz GA, et al. Toenail trace element levels and breat cancer. AmJ Epidemiol 1996;144:653-60.
13. Cerulli J, Grabe DW, Guathier I, et al. Chromium picolinate toxicity. Ann Pharmacother 1998;32:428-31.
14. Wasser WG, Feldman NS. Chromic renal failure after ingestion of over-the-counter chromium picolinate. Ann Intern Med 1997;126:410 [letter].
15. Offenbacher EG. Promotion of chromium absorption by ascorbic acid. Trace Elements Electrolyte 1994;11:178-81.

  • Back To List
  • Wholesaler/Distributor Registration   l  My Cart   l   My Account  l  Home  l  Return to Top of Page

        Nasvhille Chamber of Commerce Dickson County Chamber of Commerce U.S. Commercial Service

    *These statements have not been evaluated by the F.D.A. *USA Laboratories makes no representation or warranties concerning the use of our products for the diagnosis, cure, mitigation, treatment or prevention of any disease. *Seek advice from a health care provider before using this or any supplement product.

    Powered By LionZone Copyright © USA LABORATORIES, INC. All rights reserved.